GlobeNewswire Inc | Jul 22, 2021 12:11PM EDT

July 22, 2021

PRESS RELEASE

AB SCIENCE TO PRESENT RESULTS FROM ITS PHASE III AB09004 STUDY IN MILD TO MODERATE ALZHEIMERS DISEASEAT THE WORLD'S LARGEST CONFERENCE FOR ALZHEIMERS AND DEMENTIA RESEARCH (AAIC 2021)

Paris, 22July, 2021, 6pm CET

AB Science SA (Euronext - FR0010557264 - AB) today announced that an abstract reporting results from its Phase 3 AB09004 study on Alzheimers disease has been selected for an oral presentation at the annual Alzheimers Association International Conference (AAIC) (July 26-30, 2021).

The AAIC is the largest and most influential international meeting dedicated to the latest Alzheimers and dementia research. Last years virtual conference event attracted over 31,000 registered attendees and more than 3,000 scientific presentations. This year the Alzheimers Association International Conference (AAIC) is taking place both in person (Denver, USA) and online (hybrid model of delivery).

Professor Bruno Dubois, director of the Institute of Memory and Alzheimers Disease at the Piti-Salptrire Hospital in Paris and coordinating investigator of study AB09004, will present key results as part of the meetings session on human clinical trials.

Details for the presentation are as follows:Presentation Title: Masitinib in mild to moderate Alzheimers disease: Results from study AB09004Date and time: Thursday, July 29, 2021, 8:00 AM - 9:15 AM (MT)

Professor Olivier Hermine, President of the Scientific Committee of AB Science and member of the Acadmie des Sciences in France, said: There is an urgent need for innovativedrug development approaches that targetnon-amyloid pathways in the fight against Alzheimer's disease. Selection of this abstract for an oral presentation at this years Alzheimers Association International Conference is an indication of masitinibs potential impact on the treatment landscape for mild to moderateAlzheimers disease and also of the level of interest being generated by this groundbreaking approach.

About masitinibMasitinib is an orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases. Based on its unique mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and microglia and consequently the inhibition of the activation of the inflammatory process, masitinib can have an effect on the symptoms associated with some inflammatory and central nervous system diseases and the degeneration of these diseases.

About AB ScienceFounded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment. AB Science has developed a proprietary portfolio of molecules and the Companys lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

Further information is available on AB Sciences website: www.ab-science.com.

Forward-looking Statements - AB ScienceThis press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance.

These forward-looking statements can often be identified by the words "expect", "anticipate", "believe", "intend", "estimate" or "plan" as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents published by AB Science. AB Science disclaims any obligationor undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations.

For additional information, please contact:

AB ScienceFinancial Communication & Media Relations investors@ab-science.com

Media Relations USA

RooneyPartnersKate Barrettekbarrette@rooneyco.com

+1646432 0191

Media Relations France

NewCapArthur Rouillarouille@newcap.fr

+33 (0)1 44 71 00 15

Attachment

-- CP AAIC2021 preview vEng VF